glp 1 drugs and autoimmune disease GLP-1 Agonists in The Thyroid Twist: How GLP-1

Indication Segment Insights and Analysis: Based on the indication, the GLP-1 Receptor Agonist market is segmented into type 2 diabetes, obesity, cardiovascular diseases, liver cirrhosis, Non-alcoholic fatty liver disease (NAFLD), and others

[DOI] [PubMed] [Google Scholar] 69.Laiteerapong N, Ham SA, Gao Y, et al

Moreover, it explores the potential of GLP-1 agonists and SGLT-2 inhibitorstherapeutic agents that have shown promise in non-liver transplant populationsas novel approaches to mitigate the effects of these complications in liver transplant recipients

Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects

Patients who have a history of ASCVD, no significant history of recurrent genitourinary infections or bladder cancers, and without risk factors for DKA or fractures may be good candidates for SGLT2-I

GLP-1 Receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes